You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Developing a novel adjuvant system for therapeutic vaccines against lung cancer

    SBC: FasCure Therapeutics LLC            Topic: 102

    DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Automated Object Contouring Methods & Software for Thoracic Radiotherapy Planning

    SBC: Quantitative Radiology Solutions LLC            Topic: 102

    DESCRIPTION provided by applicant In nearly million new cancer cases are estimated to occur in the US where nearly two thirds will have treatment by radiation therapy In current clinical practice organ contour delineation on medical images is still performed with low levels of automation due to lack of highly automated commercial contouring software This deteriorates therapy plann ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Novel immunotherapy strategy for treatment of pancreatic cancer

    SBC: Oncotab, Inc.            Topic: NCI

    DESCRIPTION provided by applicant Pancreatic cancer has the worst prognosis of all cancers and is the fourth leading cause of cancer related deaths in the United States Patients usually present with advanced disease making curative attempts difficult Surgery is the only curative therapy since radiotherapy and chemotherapy remain largely ineffective coupled with undesirable side effects Desp ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer

    SBC: 7 Hills Pharma LLC            Topic: 102

    DESCRIPTION provided by applicant Recent FDA approvals of ipilimumab nivolumab and pembrolizumab which target checkpoint receptors cytotoxic T lymphocyte associated antigen CTLA and programmed death PD have ushered in a new era of cancer immunotherapy in metastatic melanoma Despite unprecedented overall survival benefits with combination therapy the incidence of complete respo ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. A cloud-based secure patient information exchange framework for managing treatment accessibility, utilization, quality, and outcomes in behavioral health clinics

    SBC: Waldron International llc            Topic: NIDA

    DESCRIPTION In communities across the United States clinical populations exhibiting mental health and or substance abuse disorders face substantial challenges in accessing and receiving high quality and effective behavioral healthcare services Health Information technology HIT has been identified as an important component of improving access to behavioral healthcare in rural communities yet t ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Orally Bioavailable Gadolinium Chelators for Preventing and Ameliorating Toxicity Due to MRI Contrast Agents

    SBC: Capture Pharmaceuticals, Inc.            Topic: 102

    DESCRIPTION provided by applicant Capture Pharmaceuticals Inc is developing a drug called C E initially intended for treatment of individuals who have been contaminated by radioactive actinide elements following a nuclear terrorism event Because of the similarities between actinides and lanthanides it is expected that C E will also be effective in removing gadolinium Gd a lanthanide in ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Delivery of pathogen trapping antibodies for vaginal protection

    SBC: MUCOMMUNE, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Despite immense efforts in behavioral interventions to promote safer sexual practices sexually transmitted infections STIs continue to be a pandemic worldwide Unfortunately there are no effective vaccines or microbicides for the majority of STIs A pathogen specific safe effective and discreet vaginal microbicide that does not require daily or sex associ ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Small Molecule Antibiotic Potentiators for Drug-Resistant Bacteria

    SBC: AGILE SCIENCES, INC.            Topic: NIAID

    DESCRIPTION provided by applicant An estimated two million Americans suffer from infections caused by multi drug resistant MDR bacteria resulting in a substantial impact on patientsandapos lives and an extraordinary economic burden Due to the arsenal of antibiotic resistance mechanisms that these bacteria present traditional antibiotic therapies are often ineffective New strategies that u ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Optimization of the Production and Isolation of the Novel Antifungal Occidiofungin

    SBC: Sano Chemicals, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Occidiofungin is a cyclic nonribosomally synthesized antifungal peptide with submicromolar fungicidal activity against a broad spectrum of fungi Occidiofungin is produced by the Gram negative bacterium Burkholderia contaminans From our structural characterization studies occidiofungin was determined to have a unique chemical composition Our studies have als ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. New piperazines effecting Abeta oligomer displacement from neuronal receptors

    SBC: COGNITION THERAPEUTICS, INC.            Topic: NIA

    DESCRIPTION provided by applicant Cognition Therapeutics Inc andapos s mission is to develop effective therapeutics for Alzheimerandapos s disease Recent scientific discoveries have identified oligomers of the brain protein Abeta as toxic culprits in the disease process Cognition has discovered therapeutic molecules that displace Abeta oligomers from neurons and block the downstream pathol ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government